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hearts. Nature. 2014;510:273-7.MMENTARYCardiac stem cell therapy: Checkered past, promising future?John J. Squiers, BSE,a Kelley A. Hutcheson,MD,b Jeffrey E. Thatcher, PhD,c and J. Michael DiMaio, MDc,dIn this issue of the Journal of Thoracic and Cardiovascular
Surgery (JTCVS), Luo and colleagues1 have demonstrated a
novel approach to transplantation of human embryonic stem
cell grafts within infarcted myocardium in an animal model.
We commend their emphasis on transplanting stem cell
grafts as directionally oriented, infarct-spanning bands.
Often missing from basic science laboratories is the under-
standing of the importance of these macroscopic helical
Torrent-Guasp myocardial bands2 that allow for torsional
deformation of the left ventricle during systole and, thus,
appropriate ventricular function. By submitting their work
to JTCVS, Luo and colleagues recognize that cardiac sur-
geons, who handle the human heart on a near daily basis,
can best appreciate the importance of the heart’s macro-
architecture for effective cardiac function.
Their demonstrated effects of CoPP preconditioning
represent an important step forward in our understanding
of the basic mechanisms and principles underlying regener-
ative stem cell therapy. This bench-top research is crucial toassist clinicians in achieving better clinical outcomes with
cardiac stem cell therapy. In light of this success, however,
it is essential to recognize the often-frustrating discordance
between results of promising basic science research and
more humbling clinical trials over the last 15 years of inves-
tigation into stem cell therapy for cardiac disease.
Extensive research efforts have investigated the potential
for stem cell–mediated cardiac tissue regeneration in the
treatment of cardiovascular disease.3 Early basic science re-
ports suggested enormous therapeutic potential,4 but results
from clinical trials have been disappointing to date. Basic
investigators have employed various kinds of stem cells:
embryonic stem cells (ESCs), induced pluripotent stem
cells (iPSCs), and adult progenitor cells (including skeletal
myoblasts, bone marrow mononuclear cells [BMMNCs],
and cardiac stem cells [CSCs]). So far, however, completed
clinical trials have only reported transplantation of the
various adult progenitor cells. In fact, a casual review of
the clinical trials database (clinicaltrials.gov/ct2/home)
shows that the overwhelming majority of trials has em-
ployed or will employ adult progenitor stem cells rather
than truly pluripotent ESCs or iPSCs.
An early clinical trial of skeletal myoblasts (Myoblast
Autologous Grafting in Ischemic Cardiomyopathy
[MAGIC]5) was discontinued prematurely after both a
lack of efficacy and an increased risk for arrhythmias in pa-
tients receiving stem cell therapy were demonstrated. A
more recent skeletal myoblast trial (ie, SEISMIC6) did not
reveal any effect of stem cell therapy on the left-
ventricular ejection fraction (LVEF). Although BMMNCs
have been the most commonly employed cell type for
stem cell therapy trials (eg, REPAIR-AMI,7 TIME,8
POSEIDON9), these investigations have also yielded
underwhelming results. Meta-analyses of BMMNC trialsgery c December 2014
TABLE 1. Meta-analyses of bone marrow cell therapy for cardiac disease, encompassing 3 major indications10-12
Study Indication
No. of
trials
No. of
patients D LVEF (%) Notes
Fisher et al (2013)10 Refractory angina
or HF
9 659 þ3.47  1.59 Reduced mortality with cell therapy
(RR ¼ 0.33, 0.17-0.65)
Kandala et al (2013)11 Chronic heart
failure
10 519 þ4.48  2.05 Intramyocardial injection may be superior to
intracoronary infusion in patients with LV systolic
dysfunction
Delewi et al (2014)12 Acute STEMI 16 1641 þ2.55  0.72 Improvement better in young patients (<55 y) and
patients with low LVEF (<40% baseline)
LVEF, Left ventricular ejection fraction; HF, heart failure; RR, relative risk; LV, left ventricle; STEMI, ST-segment elevation myocardial infarction.
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only minimal increases in LVEF across the board
(Table 110-12). Two trials implementing CSCs (SCIPIO13
and CADUCEUS14) were ineffective in improving
meaningful clinical outcomes. Additional trials with adult
progenitor cells are currently ongoing, including the
ATHENA trial,15 which is utilizing adipose-derived regen-
erative cells for transplantation.16
After this surge of clinical trials employing adult progen-
itor stem cells yielded largely disappointing results,
research efforts have been wisely redirected from the clinic
back to the laboratory. In this effort to better understand the
underlying principles of cardiac stem cell therapy, basic sci-
entists and clinicians have learned from the mistakes of
prior trials and sought solutions to challenging questions
in the field, but many questions remain about basic mecha-
nisms of stem cell therapy in cardiac regeneration.17 Gar-
bern and Lee18 have recently outlined several of these
questions expertly, 4 of which we highlight below:
1. What is the precise mechanism of action by which
stem cell transplantation may demonstrate clinical
efficacy?
Perhaps the most intuitive explanation for the therapeutic
effects of stem cell transplantation is what we call the
Cardiomyocyte Replacement Theory. According to this
theory, transplanted stem cells differentiate into functional
cardiomyocytes that integrate into the existing myocardial
architecture to increase cardiac function through additional
mechanical force. Nevertheless, data have consistently indi-
cated that the vast majority of transplanted adult progenitor
stem cells do not persist in their new ischemic environment
for a prolonged period of time. Long-term engraftment rates
have been shown to be<1%. These rates are so low because
90% of delivered cells are washed out of the heart within
24 hours, and approximately 90% of any remaining cells
die within the first week of transplant.3,17 In fact, the
beneficial effects of stem cell transplantation often
paradoxically outlast the survival of transplanted stem
cells in the ischemic heart tissue. Therefore, a second
theory, which emphasizes unspecified paracrine effects of
transplanted stem cells, has recently gained traction.19The Journal of Thoracic and CarThis theory, which we call the Cardiomyocyte Repair
Theory, suggests that trophic factors released by stem cells
stimulate existing cardiomyocytes, leading to an increase
in cardiac function.
It remains to be determined which specific factors are
actually released by stem cells or how they promote benefi-
cial cardiac effects. Proposed mechanisms of the Cardio-
myocyte Repair Theory include stimulation of endogenous
cardiac progenitor cell populations, enhanced tissue repair,
improved angiogenesis, and matrix remodeling to reduce
fibrosis.20 Of note, a consensus18 has recently emerged
that the mammalian heart is capable of creating a limited
number of cardiac cells after birth and that some vertebrates,
including neonatal mice, can regenerate the myocardium af-
ter experimentally induced ischemia.21 Various mechanisms
have been proposed to explain how cardiomyocytes may
innately regenerate following injury, as summarized in
Figure 1. These include a signaling cascade that activates
dormant progenitor cells, the proliferation of existing cardi-
omyocytes, activation of the epicardium, or the de-
differentiation of cardiomyocytes into progenitor cells that
then proliferate.18 The proposed paracrine effects of stem
cell therapy likely promote some or all of these innate path-
ways to increase function in the face of cardiac disease.
The authors of this editorial favor the Cardiomyocyte
Repair Theory as compared to the Cardiomyocyte Replace-
ment Theory to explain the effects demonstrated after trans-
plantation of adult progenitor stem cells. In fact, with
various other colleagues, 2 of the authors have previously
demonstrated important findings, involving identification
of both potential trophic factors and mechanisms of repair,
that lend credence to the paracrine cardiac repair paradigm.
With Bock-Marquette and colleagues,22,23 DiMaio and
Thatcher identified a trophic factor, thymosin b4, that
promotes cardiomyocyte migration, survival, and repair.
In addition, thymosin b4 is capable of organwide
activation of the embryonic coronary developmental
program in the adult mammalian heart after systemic
administration. With Huang, Olson, and colleagues,24
DiMaio and Thatcher have also outlined how activation of
the epicardium by specific transcription factors plays a
role in myocardial repair following ischemic injury.diovascular Surgery c Volume 148, Number 6 3189
FIGURE 1. Proposed mechanisms for cardiac regeneration. Therapeutic effects of stem cells likely promote some or all of these innate pathways in the
treatment of cardiac disease. (1) Paracrine factors promote proliferation of cardiomyocytes. (2) Progenitor cells activate and differentiate into cardiomyo-
cytes. (3) Mature cardiomyocytes dedifferentiate to reenter the cell cycle and proliferate into new cardiomyocytes. (4) Activated epicardium stimulates
angiogenesis and/or proliferation of cardiomyocytes. (Figure adapted from Cell Stem Cell, Vol. 12, Garbern JC, Lee RT, Cardiac stem cell therapy and
the promise of heart regeneration, p. 692, Copyright 2013, with permission from Elsevier.18)
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creases in cardiac function in animal models following
stem cell transplantation may be due to paracrine effects
on the endogenous cardiomyocyte population rather than
cardiomyocyte replacement via stem cell differentiation
processes.
2. Which cell type is best suited for transplantation
therapy in cardiac disease?
Although the cardiomyocyte repair theory is gaining
wide acceptance as the proper explanation of the results
in successful basic science investigations employing adult
progenitor stem cells, the next generation of stem cell trials
will likely involve transplantation of ESCs and iPSCs.20 In
theory, ESCs and iPSCs could be better suited for stem cell
therapy because of their ability to fully differentiate into
functional cardiomyocytes as compared to the more limited,
less versatile cell lines used in the clinical trials previously
discussed. Thus, in addition to paracrine effects, future3190 The Journal of Thoracic and Cardiovascular Surstem cells employed in regenerative therapy may have
greater potential to persist as directionally oriented,
infarct-spanning bands that will improve the mechanical
performance of the left ventricle in systole.20 In other
words, these truly pluripotent cells could promote therapeu-
tic effects via mechanisms uniting the Cardiomyocyte
Regeneration and Cardiomyocyte Repair Theories.
Many questions remain about how truly pluripotent cells
can be optimized in stem cell therapy. The ethical concerns
involving ESCs may ultimately preclude their utility in the
clinical setting. iPSCs circumvent this ethical controversy,
but the development of a cost-effective protocol to create
sufficient quantities of iPSCs for clinical therapy is
currently a challenge.18 Even given a sufficient quantity
of pluripotent stem cells, further investigations must deter-
mine in what state these cells should be transplanted.20
Theoretically, pluripotent cells could be delivered as
cardiomyocyte progenitors, fetal-like cardiomyocytes, or
adult-like cardiomyocytes. Furthermore, these cells couldgery c December 2014
TABLE 2. Advantages and disadvantages of the various stem cell delivery methods24
Method Least invasive Cell retention Low risk* Clinical experience Notes
Epicardial B C ◔ I Delivery via mini-thoracotomy or with open heart
procedure
Transendocardial I ◕ ◔ I Requires delivery of percutaneous catheter to left
ventricle
Intracoronary ◕ I I C Preferred method during acute MI
Retrograde coronary sinus ◔ I I ◔ Optimal in cases of severe coronary stenosis
Intravenous C B C ◔ Very low retention due to cell trapping in lungs
MI, Myocardial infarction. *Common risks include perforation of the ventricular wall, cardiac arrhythmia secondary to local tissue inflammation, or embolus of the stem cells and/
or viscous delivery suspension.
Squiers et al Editorial Commentarydifferentiate to become ventricular, atrial, or nodal cells, or
even some combination of all 3. Much work still remains
before it can be determined which option(s) may produce
the greatest clinical efficacy.
3. What is the optimal delivery method for transplanta-
tion of stem cells?
Several delivery mechanisms have been previously
employed including intramyocardial (epicardial orFIGURE 2. Approaches to cardiac regeneration in heart disease. In addition to
tive therapies. (2) Tissue engineering combines cells with mechanical support a
be isolated from stem cell cultures and delivered as small molecules to promote
the delivery of viruses, small molecules, or microRNAs. All of these mechan
described in Figure 1. (Figure adapted with permission.18)
The Journal of Thoracic and Cartransendocardial), intracoronary, retrograde coronary sinus,
and systemic intravenous. Each method has significant ad-
vantages and disadvantages as described byDib et al.25 In ex-
change for increased accuracy of delivery, the most invasive
delivery routes carry a risk of perforation, arrhythmia, or
embolus of cells and/or the viscous delivery suspension.
On the other hand, poor cell homing and retention limit the
effectiveness of less invasive procedures and require the de-
livery of an increased number of cells to achieve a(1) stem cell delivery, several other related methods may prove to be effec-
nd adjunctive biomaterials that promote survival. (3) Paracrine factors may
repair and regeneration. (4) Noncardiomyocytes may be reprogrammed via
isms may promote one or more of the pathways for cardiac regeneration
diovascular Surgery c Volume 148, Number 6 3191
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delivery methods is presented in Table 2. No consensus has
been reached upon how best to deliver stem cells to damaged
cardiac tissue,18 and it is likely that different methods
may ultimately prove to be superior depending on the
particular indication for stem cell therapy. For example, in-
tracoronary delivery is the preferred route of transplant in pa-
tients suffering acute myocardial infarct.17,25 Again, we
commend Luo and colleagues1 for addressing lingering ques-
tions about cell delivery by employing an injectable delivery
method designed to regenerate Torrent-Gausp myocardial
bands. In particular, their attempt to replicate the physiologic
architecture of the human heart via stem cell transplantation
represents a novel solution for optimal delivery.
4. What adjuvants to cell delivery will maximize the
benefits of stem cell therapy?
Recent investigations have demonstrated many methods
to quantitatively assess cell engraftment and survival
following delivery in the laboratory.26 Experiments have
consistently revealed that both engraftment and survival
rates are extremely low regardless of the cell type or deliv-
ery mechanism implemented. Both cardiac blood flow,
which washes away stem cells after intracoronary delivery,
and myocardial contraction, which accentuates leakage of
cells from an injection site, limit cell retention.26 In addi-
tion, ischemic conditions severely inhibit the survival of
any cells that successfully engraft by 24 hours posttrans-
plant, as at least 90% of engrafted cells die within the first
week. These factors limit total cell survival following trans-
plant to<1% overall.3,17 Reasonable estimates suggest that
approximately 1 billion cardiomyocytes are required to
completely replace all of the cells from the working
myocardium that is lost during a myocardial infarction.27
At current cell survival rates, stem cell therapy would
require the transfer of up to 1 trillion cells (roughly equiv-
alent to 3% of the total number of cells in the human
body) to each patient in order to completely replete the
devastated cell population.
Therefore, various methods of tissue engineering have
been investigated as adjuvant support to improve the persis-
tence of stem cells following transplant. By increasing the
viability of stem cells, these methods would allow for fewer
stem cells to be transplanted while concurrently bettering
clinical outcomes. Examples include cell co-culturing,
biomaterial formulation, and genetic engineering of cells.17
Cell co-culturing involves pretreating stem cells with
various cofactors that induce favorable cell-signaling path-
ways to increase cell survival and/or homing accuracy
following transplantation. Biomaterials, in which cells are
engrafted, may be applied as epicardial patches that in-
crease cell retention and survival via mechanical scaf-
folding to limit cell washout or controlled released of
biologic agents to support cells in ischemic environments.283192 The Journal of Thoracic and Cardiovascular SurMany attempts at genetic engineering of cells prior to deliv-
ery have been reported, but several concerns about this
manner of adjunctive therapy have been raised.26 Specif-
ically, how can we ensure genetic manipulation increases
cell survival without interfering with proper myocardial
function or without introducing a significant risk of onco-
genesis? Further research is needed to elucidate which adju-
vant therapies can be optimally combined with stem cell
transplantation to increase cardiac function.
In addition to tissue engineering of stem cells, other tech-
niques to promote cardiac repair have been proposed. These
include the direct delivery of paracrine factors isolated from
stem cell colonies and the reprogramming of noncardio-
myocytes into cardiomyocytes using growth factors or mi-
croRNA assays as described elsewhere.18 Figure 2
provides a summary of these approaches to cardiac regener-
ation therapy. Ultimately, all of these methods likely pro-
mote some combination of the innate cardiac repair
pathways summarized above.
To these questions, which are currently under investiga-
tion in the laboratory, we add our own, which cannot be
resolved with basic science research alone: How can clin-
ical trials best assess stem cell therapy in a clinically signif-
icant manner? Most completed trials have published
outcomes by employing metrics such as changes in LVEF,
left ventricular end-diastolic volume, and/or left ventricular
end-systolic volume.Many of these trials have shown statis-
tically significant, but clinically disappointing, improve-
ments in these metrics. We wonder, moreover, how
meaningful these metrics are to clinicians and their patients,
especially given the operator-depended variability inherent
in acquiring such measurements in addition to the physio-
logic variability of measurements of the same patient under
different loading conditions.We believe that more clinically
relevant outcomes, such as VO2max and cardiac perfusion,
must receive greater attention in future clinical trials. Other
useful parameters include heart failure and angina classifi-
cations, quality of life metrics, and physical exercise perfor-
mance.10 Of course, we cannot lose sight of the most
clinically significant outcomes, morbidity and mortality,
as stem cell therapy becomes more widespread.
Ultimately, the initial promise of stem cell transplantation
research has not yielded as much success as initially hoped
during the first round of clinical trials. More basic science
investigation is required to elucidate the specific mecha-
nism(s) by which transplanted stem cells promote cardiac
regeneration and/or repair, which stem cell type is most
effective, and how cells can be optimally delivered and engi-
neered. As our understanding of stem cell therapy increases,
it becomes more likely that clinical trials can produce truly
meaningful results with implications for clinical practice.
Another wave of stem cell clinical trials is fast approaching,
as the NIH Heart, Lung, and Blood Institute teams with the
Cardiothoracic Surgical Trials Network (CTSN) to fund andgery c December 2014
Squiers et al Editorial Commentaryperform this research in multicentered trials.29 We remain
cautiously optimistic that further investigations will yield
more promising results than the first round of clinical trials,
but we emphasize the tremendous challenges yet to be over-
come before stem cell therapy can be a realistic therapeutic
option for clinicians and their patients.References
1. Luo J, Weaver MS, Dennis JE, Whalen E, Laflamme MA, Allen MD. Targeting
survival pathways to create infarct-spanning bridges of human embryonic stem
cell-derived cardiomyocytes. J Thorac Cardiovasc Surg. 2014;148:3180-8.
2. Torrent-Guasp F, Ballester M, Buckberg GD, Carreras F, Flotats A, Carrio I, et al.
Spatial orientation of the ventricular muscle band: physiologic contribution and
surgical implications. J Thorac Cardiovasc Surg. 2001;122:389-92.
3. Malliaras K, Marban E. Cardiac cell therapy: where we’ve been, where we are,
and where we should be headed. Br Med Bull. 2011;98:161-85.
4. Tomita S, Li R,Weisel RD,Mickle DAG, Kim E, Sakai T, et al. Autologous trans-
plantation of bone marrow cells improves damaged heart function. Circulation.
1999;100:II-247-56.
5. Menasche P, Alfieri O, Janssens S, McKenna W, Reichenspurner H, Trinquart L,
et al. The Myoblast Autologous Grafting in Ischemic Cardiomyopathy (MAGIC)
trial: the first randomized placebo-controlled study of myoblast transplantation.
Circulation. 2008;117:1189-200.
6. Duckers HJ, Houtgraaf J, Hehrlein C, Schofer J, Waltenberger J, Gershlick A,
et al. Final results of a phase IIa, randomized, open-label trial to evaluate the
percutaneous intramyocardial transplantation of autologous skeletal myoblasts
in congestive heart failure patients: the SEISMIC trial. EuroIntervention. 2011;
6:805-12.
7. Assmus B, Rolf A, Erbs S, Els€asser A, Haberbosch W, Hambrecht R, et al.,
REPAIR-AMI Investigators. Clinical outcome 2 years after intracoronary admin-
istration of bone marrow-derived progenitor cells in acute myocardial infarction.
Circ Heart Fail. 2010;3:89-96.
8. Traverse JH, Henry TD, Pepine CJ, Willerson JT, Zhao DX, Ellis SG, et al. Effect
of the use and timing of bone marrow mononuclear cell delivery on left ventric-
ular function after acute myocardial infarction: the TIME randomized trial. J Am
Med Assoc. 2012;308:2380-9.
9. Hare JM, Fishman JE, Gerstenblith G, Velazquez DLD, Zambrano JP,
Suncion VY, et al. Comparison of allogeneic vs autologous bone marrow-
derived mesenchymal stem cells delivered by transendocardial injection in pa-
tients with ischemic cardiomyopathy: the POSEIDON randomized trial. J Am
Med Assoc. 2012;308:2369-79.
10. Fisher SA, Doree C, Brunskill SJ, Mathur A, Martin-Rendon E. Bone marrow
stem cell treatment for ischemic heart disease in patients with no option of
revascularization: a systemic review and meta-analysis. PLoS One. 2013;8:
e64669.
11. Kandala J, Upadhyay GA, Pokushalov E, Wu S, Drachman DE, Singh JP. Meta-
analysis of stem cell therapy in chronic ischemic cardiomyopathy. Am J Cardiol.
2013;112:217-25.The Journal of Thoracic and Car12. Delewi R, Hirsch A, Tijssen JG, Sch€achinger V, Wojakowski W, Roncalli J, et al.
Impact of intracoronary bone marrow cell therapy on left ventricular function in
the setting of ST-segment elevation myocardial infarction: a collaborative meta-
analysis. Eur Heart J. 2014;35:989-98.
13. Bolli R, Chugh AR, D’Amario D, Loughran JH, StoddardMF, Ikram S, et al. Car-
diac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial re-
sults of a randomized phase 1 trial. Lancet. 2011;378:1847-57.
14. MakkarRR, SmithRR,ChengKE,MalliarasK,ThomsonLE,BermanD, et al. Intra-
coronary cardiosphere-derived cells for heart regeneration aftermyocardial infarction
(CADUCEUS): a prospective, randomised phase 1 trial. Lancet. 2012;379:895-904.
15. Cytori Therapeutics. Safety and feasibility trial of adipose-derived regenerative
cells in the treatment of chronic myocardial ischemia. Available at: http://
www.clinicaltrials.gov/ct2/show/NCT01556022?term¼cytori&rank¼3. Ac-
cessed October 7, 2014.
16. Zuk PA, ZhuM, Ashjian P, De Ugarte DA, Huang JI, Mizuno H, et al. Human ad-
ipose tissue is a source of multipotent stem cells.Mol Biol Cell. 2002;13:4279-95.
17. Malliaras K, Kreke M,Marban E. The stuttering progress of cell therapy for heart
disease. Clin Pharmacol Ther. 2011;90:532-41.
18. Garbern JC, Lee RT. Cardiac stem cell therapy and the promise of heart regener-
ation. Cell Stem Cell. 2013;12:689-98.
19. Williams AR, Hare JM. Mesenchymal stem cells: biology, pathophysiology,
translational findings, and therapeutic implications for cardiac disease. Circ
Res. 2011;109:923-40.
20. ProwseABJ,TimminsNE,YauTM,LiR,WeiselRD,KellerG, et al. Transforming
the promise of pluripotent stem cell derived cardiomyocytes to a therapy: chal-
lenges and solutions for clinical trials. Can J Cardiol. 2014;30:1335-49.
21. PorelloER,MahmoudAI, SimpsonE,Hill JA,Richardson JA,OlsonEN, et al.Tran-
sient regenerative potential of the neonatalmouseheart.Science. 2011;331:1078-80.
22. Bock-Marquette I, Saxena A, White MD, DiMaio JM, Srivastava D. Thymosin
b4 activates integrin-linked kinase and promotes cardiac cell migration, survival
and cardiac repair. Nature. 2004;432:466-72.
23. Bock-Marquette I, Shrivastava S, Pipes GC, Thatcher JE, Blystone A,
Shelton JM, et al. Thymosin b4 mediated PKC activation is essential to initiate
the embryonic coronary developmental program and epicardial progenitor cell
activation in adult mice in vivo. J Mol Cell Cardiol. 2009;46:728-38.
24. Huang GN, Thatcher JE, McAnally J, Kong Y, Qi X, Tan W, et al. C/EBP tran-
scription factors mediate epicardial activation during heart development and
injury. Science. 2012;338:1599-603.
25. Dib N, Khawaja H, Varner S, McCarthy M, Campbell A. Cell therapy for cardio-
vascular disease: a comparison of methods of delivery. J Cardiovasc Transl Res.
2011;4:177-81.
26. Terrovitis JV, Smith RR, Marban E. Assessment and optimization of cell engraft-
ment after transplantation into the heart. Circ Res. 2010;106:479-94.
27. Mummery CL, Zhang J, Ng ES, Elliott DA, Elefanty AG, Kam TJ. Differentia-
tion of human ES and iPS cells to cardiomyocytes: a methods overview.Circ Res.
2012;111:344-58.
28. Menasche P. How close are we to using stem cells in routine cardiac therapy?Can
J Cardiol. 2014;30:1265-9.
29. Ascheim DD, Gelijns AC, Goldstein D, Moye LA, Smedira N, Lee S, et al.
Mesenchymal precursor cells as adjunctive therapy in recipients of contemporary
LVADs. Circulation. 2014;129:2287-96.diovascular Surgery c Volume 148, Number 6 3193
E
T
/B
S
